Hideto Nishitani joined ORIX USA in 2006 as Deputy President and was appointed Chairman in 2012 and President and Chief Executive Officer in 2015. Mr. Nishitani has a 32-year track record of comprehensive global financial services experience working on behalf of the ORIX Corporation in the U.K., Ireland, Canada and Japan.
Mr. Nishitani was appointed Corporate Senior Vice President of ORIX Corporation in January 2014.
Prior to joining ORIX USA, he spent a decade building his portfolio of structured finance and investment banking experience. Between 2001 and 2006, he was actively involved in the firm’s M&A and buyout investment business as Senior Vice President of the Principal Investment group of the company’s Investment Banking headquarters in Japan, where he was responsible for sourcing, acquiring, restructuring and managing portfolio companies for investment return. Since 2001 till 2006, he was a board member of MIC Medical Corporation, a CRO subsidiary of M3 Group in Tokyo (M3 is a public company listed on Tokyo Stock Exchange, majority owned by SONY Corporation).
He earned a Bachelor of Economics degree from Kwansei-Gakuin University in Japan and a Master of Economics degree from the London School of Economics, University of London. He is a member of the International Corporate Governance Network in London, the Securities Analyst Association and the Association of Turnaround Professionals in Japan.
DR. STEPHEN GATELY obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital. Thereafter he joined the Department of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine as Research Assistant Professor where his research focused on the identification and development of pharmacologic and endogenous inhibitors of angiogenesis. During this time, Dr. Gately served as a consultant to the Oncology Clinical Research Team at Searle/Monsanto (now Pfizer). In this position he was responsible for scientific and technical input on clinical trial designs to rapidly assess the utility of antiangiogenic compounds. Additional responsibilities included interacting with discovery scientists to understand drug mechanism of action to aid in the identification of potential biomarkers for early clinical proof of drug activity studies. He then joined the oncology-focused biopharmaceutical company NeoPharm where he served as Executive Director of Translational Medicine. In this position Dr. Gately had responsibility for the design and implementation of basic and clinical research studies to enhance the scientific understanding and positioning of existing products and development candidates. Dr. Gately then served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the scientific integration of non-clinical, clinical and regulatory data on portfolio compounds for optimal commercial planning. In addition he was involved in the scientific due diligence for oncology new business development opportunities. Dr. Gately is currently President and Chief Executive Officer at Translational Drug Development (TD2), and adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine.
Dr. Jeffrey M. Trent is President and Research Director of the Translational Genomics Research Institute (TGen) in Phoenix, Arizona.
Prior to forming TGen in 2002, Dr. Trent served for 10 years as the Scientific Director of the National Human Genome Research Institute at the National Institutes of Health in Bethesda, Maryland. Under his guidance, NHGRI’s Division of Intramural Research became an internationally recognized research center in human genetics.
Dr. Trent’s research has provided important insights into the genetic basis of cancer. He is the author of more than 300 manuscripts in the scientific literature, numerous book chapters, invited reviews, and has given hundreds of invited lectures. He has received numerous honors and awards, and has sat on the editorial boards of a dozen scientific publications. He specializes in developing and integrating novel “omic” technologies, supporting studies of molecular changes related to cancer risk and progression. He continues to participate in studies of other complex diseases in humans, as well as leading TGen’s canine hereditary cancer program.
Dr. Trent’s previous faculty positions included: The University of Arizona, where he was Deputy Director and Director for Basic Science of the Arizona Comprehensive Cancer Center; the University of Michigan, where he held the E. Maisel Endowed Professorship in Cancer Genetics, Professor of Human Genetics and Radiation Oncology, Head of the Cancer Biology Division of the Department of Radiation Oncology, and Deputy Director and Director of Basic Research for the Michigan Comprehensive Cancer Center. He also is a Diplomat of the American College of Medical Genetics.Work in Dr. Trent’s laboratory focuses on the study of genetic changes related to cancer predisposition and progression. He has worked the majority of his career on melanoma, most recently serving as the Co-Principal Investigator of the Stand Up to Cancer Melanoma Dream Team. The focus on that project is using molecularly-guided therapy for patients with BRAF wild-type (BRAFwt) metastatic melanoma. In addition to continuing work on germline genetic alterations associated with melanoma risk, his laboratory has been among the most active in identifying and understanding the somatic changes associated with canine melanoma. The canine is a critically important model of human disease, and in the case of melanoma the clear clinical association to the human is for the largely understudied mucosal melanomas.